FI930220L - Oligonukleotidsanaloger, deras framstaellning och anvaendning - Google Patents

Oligonukleotidsanaloger, deras framstaellning och anvaendning Download PDF

Info

Publication number
FI930220L
FI930220L FI930220A FI930220A FI930220L FI 930220 L FI930220 L FI 930220L FI 930220 A FI930220 A FI 930220A FI 930220 A FI930220 A FI 930220A FI 930220 L FI930220 L FI 930220L
Authority
FI
Finland
Prior art keywords
analoger
oligonucleotide
deras framstaellning
framstaellning och
och anvaendning
Prior art date
Application number
FI930220A
Other languages
English (en)
Other versions
FI115214B (fi
FI930220A0 (fi
Inventor
Eugen Uhlmann
Anuschirwan Peyman
Gerard O'malley
Matthias Helsberg
Irvin Winkler
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of FI930220A0 publication Critical patent/FI930220A0/fi
Publication of FI930220L publication Critical patent/FI930220L/fi
Application granted granted Critical
Publication of FI115214B publication Critical patent/FI115214B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
FI930220A 1992-01-22 1993-01-20 Menetelmä oligonukleotidianalogien valmistamiseksi ja niiden käyttö FI115214B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4201662 1992-01-22
DE4201662 1992-01-22

Publications (3)

Publication Number Publication Date
FI930220A0 FI930220A0 (fi) 1993-01-20
FI930220L true FI930220L (fi) 1993-07-23
FI115214B FI115214B (fi) 2005-03-31

Family

ID=6450030

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930220A FI115214B (fi) 1992-01-22 1993-01-20 Menetelmä oligonukleotidianalogien valmistamiseksi ja niiden käyttö

Country Status (17)

Country Link
EP (1) EP0552766B1 (fi)
JP (1) JP3717081B2 (fi)
KR (1) KR930016437A (fi)
AT (1) ATE217880T1 (fi)
AU (1) AU661365B2 (fi)
CA (1) CA2087818C (fi)
DE (1) DE59310285D1 (fi)
DK (1) DK0552766T3 (fi)
ES (1) ES2177532T3 (fi)
FI (1) FI115214B (fi)
HU (1) HU227794B1 (fi)
IL (1) IL104461A (fi)
NO (1) NO308215B1 (fi)
NZ (1) NZ245720A (fi)
PL (1) PL172257B1 (fi)
PT (1) PT552766E (fi)
ZA (1) ZA93422B (fi)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
DK0593901T3 (da) 1992-09-24 1997-10-27 Hoechst Ag Oligoribonucleotid- og ribozym-analoge med terminale 3-3- og 5-5-bindinger.
EP0602524A1 (de) * 1992-12-15 1994-06-22 Hoechst Aktiengesellschaft Chemilumineszenzmarkierte Gensonden und ihre Verwendung in Gensondentesten
US6087491A (en) 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
ES2100051T3 (es) * 1993-01-08 1997-06-01 Hybridon Inc Sintesis de bloques dimeros y su uso en el ensamblaje de oligonucleotidos.
NZ262254A (en) * 1993-01-25 1997-10-24 Hybridon Inc Oligonucleotide analogue containing a ribonucleotide alkylphosphon(ate or thioate), gene repression
CA2114355A1 (en) * 1993-01-29 1994-07-30 Hidehiko Furukawa Modified oligodeoxyribonucleotides, their preparation and their therapeutic use
US5532130A (en) * 1993-07-20 1996-07-02 Dyad Pharmaceutical Corporation Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US6919441B2 (en) 1994-03-14 2005-07-19 Aventis Pharma Deutschland Gmbh Polyamide-oligonucleotide derivatives, their preparation and use
DE4408528A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
PL316434A1 (en) * 1994-03-18 1997-01-06 Lynx Therapeutics Oligonucleotidic phosphoramides n3'-p5', their compositions, synthesising and hydridising methods as well as immunological properties in respect to nuclease
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
DE4415370A1 (de) * 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US5986076A (en) * 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE4438918A1 (de) * 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
DE59607750D1 (de) * 1995-03-13 2001-10-31 Aventis Pharma Gmbh Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US5684143A (en) * 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) * 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
GB9606158D0 (en) * 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
PT808898E (pt) * 1996-05-24 2004-10-29 Aventis Pharma Gmbh Reagente e metodo para inibicao da expressao de n-ras
DE19627898A1 (de) * 1996-07-11 1998-01-15 Hoechst Ag Festphasensynthese von Oligonucleotiden
BR9809242A (pt) 1997-05-05 2000-06-27 Hoechst Marion Russel Deutschl Nucleotìdeos anti-sentido modificados complementares a uma seção do gene ha-ras humano
WO1999019474A1 (en) * 1997-10-14 1999-04-22 Sankyo Company, Limited Modified oligodeoxyribonucleotides having tggg sequence
EP1004661A1 (de) 1998-11-11 2000-05-31 DALLI-WERKE WÄSCHE- und KÖRPERPFLEGE GmbH & Co. KG Verdichtetes Granulat, Herstellungsverfahren und Verwendung als Sprengmittel für gepresste Formkörper (2)
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
DE19935302A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen
DE10133915A1 (de) 2001-07-12 2003-02-06 Aventis Pharma Gmbh Neue Oligoribonucleotid-Derivate zur gezielten Hemmung der Genexpression
CA2536333C (en) 2003-08-28 2013-01-08 Jan Weiler Interfering rna duplex having blunt-ends and 3'-modifications
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
CN102016036B (zh) 2008-02-11 2015-04-08 阿克赛医药公司 经修饰的RNAi多核苷酸及其用途
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
CA2743981C (en) 2008-09-22 2019-01-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
WO2015125845A1 (ja) * 2014-02-20 2015-08-27 塩野義製薬株式会社 含窒素非芳香族複素環を含む核酸のリン酸部位修飾
EP3137119B1 (en) 2014-04-28 2020-07-01 Phio Pharmaceuticals Corp. Methods for treating cancer using a nucleic acid targeting mdm2
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
KR20180026739A (ko) 2015-07-06 2018-03-13 알엑스아이 파마슈티칼스 코포레이션 슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
KR20210018267A (ko) 2018-05-07 2021-02-17 알닐람 파마슈티칼스 인코포레이티드 간외 전달

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3239888A1 (de) * 1982-10-28 1984-05-03 Hubert Prof. Dr. 2000 Hamburg Köster Verfahren zur herstellung von oligonucleosidphosphonaten
US4739044A (en) * 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4950745A (en) * 1986-10-30 1990-08-21 Daicel Chemical Industries, Ltd. Process for synthesis of oligonucleotides and compound for forming polymeric protecting group
US4816571A (en) * 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
EP0497875B1 (en) * 1989-10-24 2000-03-22 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
GB9021625D0 (en) * 1990-10-04 1990-11-21 Ici Plc Synthesis of oligonucleotides

Also Published As

Publication number Publication date
PT552766E (pt) 2002-10-31
HU227794B1 (en) 2012-03-28
NZ245720A (en) 1995-12-21
CA2087818C (en) 2007-07-10
JPH05310779A (ja) 1993-11-22
NO930199L (no) 1993-07-23
PL297515A1 (en) 1993-09-06
ZA93422B (en) 1993-09-16
FI115214B (fi) 2005-03-31
NO930199D0 (no) 1993-01-21
ATE217880T1 (de) 2002-06-15
FI930220A0 (fi) 1993-01-20
EP0552766A2 (de) 1993-07-28
HUT63173A (en) 1993-07-28
PL172257B1 (pl) 1997-08-29
AU3191093A (en) 1993-07-29
JP3717081B2 (ja) 2005-11-16
AU661365B2 (en) 1995-07-20
IL104461A0 (en) 1993-05-13
CA2087818A1 (en) 1993-07-23
EP0552766A3 (en) 1994-09-07
KR930016437A (ko) 1993-08-26
DK0552766T3 (da) 2002-08-19
NO308215B1 (no) 2000-08-14
HU9300162D0 (en) 1993-04-28
EP0552766B1 (de) 2002-05-22
IL104461A (en) 2001-05-20
DE59310285D1 (de) 2002-06-27
ES2177532T3 (es) 2002-12-16

Similar Documents

Publication Publication Date Title
FI930220L (fi) Oligonukleotidsanaloger, deras framstaellning och anvaendning
FI933857A7 (fi) Kondenserade heterocykliska foereningar, deras framstaellning och anvaendning
FI931608L (fi) Foerfarande och anordning foer terapeutisk, elektromagnetisk behandling
FI934274L (fi) N-sulfonyl-2-oxi-indolderivat, deras framstaellning och dessa innehaollande farmaceutiska kompositioner
FI931901L (fi) Azolfoereningar, deras framstaellning och anvaendning
FI931305A7 (fi) Imidazolfoereningar, deras framstaellning och bruk
FI933942L (fi) Cykliska ureaderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning
FI930620A0 (fi) Bensimidazolylderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning
FI931190A7 (fi) Triazolopyridazinfoereningar, deras framstaellning och anvaendning
FI930711L (fi) Naftalenderivat, foerfarande foer deras framstaellning och deras syntetiska mellanprodukter
FI932660L (fi) Vaermefoerseglingsbara, antistatiska belagda folier och folielaminat, foerfarande foer framstaellning av dessa och anvaendning av dessa
FI932649L (fi) Bifenylderivat, dessa foereningar innehaollande laekemedel och foerfarandefoer deras framstaellning
FI930977L (fi) Taxanderivat, deras framstaellning och onkologiska anvaendning
FI933903A7 (fi) Substituerade cyklohexanderivat, foerfarande foer framstaellning daerav och anvaendning av foereningar foer behandling av sjukdomar
FI930974L (fi) Substituerade aminofosfonatderivat, foerfarande foer framstaellning av desamma och farmaceutiska kompositioner innehaollande desamma
FI931291A0 (fi) Indol- och indazolderivat foer behandling och foerebyggande av hjaernsjukdomar, deras framstaellning och anvaendning
FI922004A0 (fi) Maetningsfoerfarande och maetanordning.
FI935829A0 (fi) Anlaeggning och foerfarande foer uttnyttjning av braennbara aemnen, speciellt industri- och hushaollsavfall
FI931599L (fi) Bensimidazoler, dessa foereningar innehaollande laekemedel och foerfarandefoer deras framstaellning
FI930130L (fi) Bundet fiberknippe, foerfarande foer framstaellning av detta och daerav erhaollna textilytstrukturer
FI930717A7 (fi) 4-amino-2-ureido-pyrimidin-5-karboxylsyraamider, foerfarande foer framstaellning av dessa, laekemedel innehaollande dessa och deras anvaendning
FI931682L (fi) Tackykininreceptorantagonister, isokinoloner och deras framstaellning
FI934221A0 (fi) Piperidinderivat, framstaellning och terapeutisk anvaendning daerav
FI932951L (fi) Tillsatskonsentrat innehaollande sulfurerat jordalkalimetallhydrokarbylfenat, foerfarande foer framstaellning av detta och anvaendning av detta
FI930236L (fi) Bensimidazoler, dessa foereningar innehaollande laekemedel och foerfarandefoer deras framstaellning

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115214

Country of ref document: FI

MA Patent expired